Physician profile
Muhammad Mujtaba
NPI 1740426592
$70,586.97
in general payments reported to CMS, 2019-2025
15 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $14K · 2023: $56K · 2024: $101 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Travel and Lodging: $6,260 · Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,400.00 |
| Travel and Lodging | $6,260.35 |
| Food and Beverage | $1,342.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $69,975.28 | 2021-2023 | Terlivaz |
| Veloxis Pharmaceuticals, INC. | $108.26 | 2023-2025 | Envarsus |
| Amgen INC. | $104.27 | 2025 | Tavneos, Krystexxa |
| Horizon Therapeutics Plc | $75.80 | 2022 | |
| Outset Medical INC | $74.40 | 2023 | |
| Merck Sharp & Dohme LLC | $49.06 | 2024 | Prevymis |
| Novo Nordisk INC | $35.87 | 2024-2025 | Rivfloza, Rybelsus, Ozempic |
| Apellis Pharmaceuticals, INC. | $28.26 | 2025 | Empaveli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.27 | 2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $24.04 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $20.77 | 2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $18.76 | 2025 | |
| Akebia Therapeutics INC | $16.98 | 2025 | Vafseo |
| Exact Sciences Corporation | $16.23 | 2025 | Cologuard Collection Kit |
| Ani Pharmaceuticals, INC. | $14.72 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Mujtaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.